Sanofi-Aventis assigned market perform by Leerink Swann

Sanofi-Aventis SA was given a market perform rating by Leerink Swann & Co. analyst Andrew Oh, who noted the company is fairly valued despite the launches of Acomplia and Exubera and projected near-term earnings growth of 16% in 2005 and 12% in 2006. The analyst cited major generic risks and the company's lack of pipeline visibility and regulatory risk around the drugs. Sanofi-Aventis closed down $0.46, or 1.07%, on Friday at $42.59 on volume of 853,600 shares compared to a three-month trailing average of 1,061,100 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.